Insmed Incorporated - Product Pipeline Review - Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Insmed Incorporated - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Insmed Incorporated - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Insmed Incorporated - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Insmed Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Insmed Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Insmed Incorporated’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Insmed Incorporated - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Insmed Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Insmed Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Insmed Incorporated’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Insmed Incorporated Snapshot
Insmed Incorporated Overview
Key Information
Key Facts
Insmed Incorporated – Research and Development Overview
Key Therapeutic Areas
Insmed Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Insmed Incorporated – Pipeline Products Glance
Insmed Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Insmed Incorporated–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Insmed Incorporated – Drug Profiles
INSM-18
Product Description
Mechanism of Action
R&D Progress
Iplex
Product Description
Mechanism of Action
R&D Progress
rhIGFBP-3
Product Description
Mechanism of Action
R&D Progress
INSM-18
Product Description
Mechanism of Action
R&D Progress
rhIGFBP-3
Product Description
Mechanism of Action
R&D Progress
Insmed Incorporated – Pipeline Analysis
Insmed Incorporated – Pipeline Products by Therapeutic Class
Insmed Incorporated Pipeline Products By Target
Insmed Incorporated – Pipeline Products by Route of Administration
Insmed Incorporated – Pipeline Products by Molecule Type
Insmed Incorporated - Dormant Projects
Insmed Incorporated - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Iplex
Insmed Incorporated – Company Statement
Insmed Incorporated – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 25, 2009: Insmed Announces Results of IPLEX Phase II Trial in Myotonic Muscular Dystrophy
Mar 10, 2009: Insmed Announces FDA Issues Statement Regarding Position On Allowing Patients With ALS Access To IPLEX Under An IND
Dec 18, 2007: Insmed Receives FDA Orphan Drug Designation for IPLEX in the Treatment of Myotonic Muscular Dystrophy
Mar 26, 2007: Insmed withdraws its marketing authorisation application for IPLEX
Mar 07, 2007: Insmed Announces Restructure, Settlement Ending IPLEX Patent Dispute
Jan 10, 2007: Italian Ministry of Health Requests IPLEX for Treatment of ALS (Lou Gehrig's Disease)
Jul 05, 2006: European Medicines Agency Validates Insmed's Regulatory Application For Marketing IPLEX in Europe
May 25, 2006: INSMED Announces IPLEX Availability Nationwide for Children with Severe Short Stature; IPLEX Launch Marked By The First Product Shipments To Patients in States Across the Country
Jan 04, 2006: U. Of Rochester Initiates Phase 2 Clinical Trial Of Insmed's IPlex For The Treatment Of Myotonic Muscular Dystrophy
Financial Deals Landscape
Insmed Incorporated, Deals Volume Summary, 2004 to YTD 2010
Insmed Incorporated, Deals Summary By Region, 2004 to YTD 2010
Insmed Incorporated, Deals Summary, 2004 to YTD 2010
Insmed Incorporated Detailed Deal Summary
Asset Purchase
Merck Acquires Biologics Business And Related Assets From Insmed
Equity Offering
Insmed Completes Public Offering Of $18 Million
Insmed Completes Public Offering of $46 Million
Insmed Completes Private Placement Of $9 Million
Debt Offering
Insmed Completes Private Placement Of 5.5% Convertible Notes For $35 Million
Insmed Enters Into Co-Development Agreement With IDIS
Insmed Signs Development Agreement With Phyton Biotech
Licensing Agreements
Insmed Enters Into Licensing Agreement With Tercica And Genentech
Insmed Enters Into Licensing Agreement With Tercica And Genentech
Insmed Enters Into Licensing Agreement With Napo Pharmaceuticals
Insmed Enters Into Licensing Agreement With Avecia
Insmed Enters Into Licensing Agreement With Tzamal
Insmed Enters Into A Licensing Agreement With Fujisawa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Insmed Incorporated – Pipeline by Therapy Area and Indication, 2010
Insmed Incorporated – Pipeline by Stage of Development, 2010
Insmed Incorporated – Monotherapy Products in Pipeline, 2010
Insmed Incorporated - Phase II, 2010
Insmed Incorporated - Phase I, 2010
Insmed Incorporated - Pipeline By Therapeutic Class, 2010
Insmed Incorporated - Pipeline By Target, 2010
Insmed Incorporated – Pipeline By Route of Administration, 2010
Insmed Incorporated – Pipeline By Molecule Type, 2010
Insmed Incorporated - Dormant Developmental Projects, 2010
Insmed Incorporated - Discontinued Pipeline Products, 2010
Insmed Incorporated, Subsidiaries
Insmed Incorporated, Deals Summary, 2004 to YTD 2010
Insmed Incorporated, Deals Summary by Region, 2004 to YTD 2010
Insmed Incorporated, Deals Summary, 2004 to YTD 2010 37
LIST OF FIGURES
Insmed Incorporated – Pipeline by Therapy Area and Indication, 2010
Insmed Incorporated – Pipeline by Stage of Development, 2010
Insmed Incorporated – Monotherapy Products in Pipeline, 2010
Insmed Incorporated – Pipeline By Therapeutic Class, 2010
Insmed Incorporated - Pipeline By Target, 2010
Insmed Incorporated – Pipeline By Route of Administration, 2010
Insmed Incorporated – Pipeline By Molecule Type, 2010 22
Insmed Incorporated Overview
Key Information
Key Facts
Insmed Incorporated – Research and Development Overview
Key Therapeutic Areas
Insmed Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Insmed Incorporated – Pipeline Products Glance
Insmed Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Insmed Incorporated–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Insmed Incorporated – Drug Profiles
INSM-18
Product Description
Mechanism of Action
R&D Progress
Iplex
Product Description
Mechanism of Action
R&D Progress
rhIGFBP-3
Product Description
Mechanism of Action
R&D Progress
INSM-18
Product Description
Mechanism of Action
R&D Progress
rhIGFBP-3
Product Description
Mechanism of Action
R&D Progress
Insmed Incorporated – Pipeline Analysis
Insmed Incorporated – Pipeline Products by Therapeutic Class
Insmed Incorporated Pipeline Products By Target
Insmed Incorporated – Pipeline Products by Route of Administration
Insmed Incorporated – Pipeline Products by Molecule Type
Insmed Incorporated - Dormant Projects
Insmed Incorporated - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Iplex
Insmed Incorporated – Company Statement
Insmed Incorporated – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 25, 2009: Insmed Announces Results of IPLEX Phase II Trial in Myotonic Muscular Dystrophy
Mar 10, 2009: Insmed Announces FDA Issues Statement Regarding Position On Allowing Patients With ALS Access To IPLEX Under An IND
Dec 18, 2007: Insmed Receives FDA Orphan Drug Designation for IPLEX in the Treatment of Myotonic Muscular Dystrophy
Mar 26, 2007: Insmed withdraws its marketing authorisation application for IPLEX
Mar 07, 2007: Insmed Announces Restructure, Settlement Ending IPLEX Patent Dispute
Jan 10, 2007: Italian Ministry of Health Requests IPLEX for Treatment of ALS (Lou Gehrig's Disease)
Jul 05, 2006: European Medicines Agency Validates Insmed's Regulatory Application For Marketing IPLEX in Europe
May 25, 2006: INSMED Announces IPLEX Availability Nationwide for Children with Severe Short Stature; IPLEX Launch Marked By The First Product Shipments To Patients in States Across the Country
Jan 04, 2006: U. Of Rochester Initiates Phase 2 Clinical Trial Of Insmed's IPlex For The Treatment Of Myotonic Muscular Dystrophy
Financial Deals Landscape
Insmed Incorporated, Deals Volume Summary, 2004 to YTD 2010
Insmed Incorporated, Deals Summary By Region, 2004 to YTD 2010
Insmed Incorporated, Deals Summary, 2004 to YTD 2010
Insmed Incorporated Detailed Deal Summary
Asset Purchase
Merck Acquires Biologics Business And Related Assets From Insmed
Equity Offering
Insmed Completes Public Offering Of $18 Million
Insmed Completes Public Offering of $46 Million
Insmed Completes Private Placement Of $9 Million
Debt Offering
Insmed Completes Private Placement Of 5.5% Convertible Notes For $35 Million
Insmed Enters Into Co-Development Agreement With IDIS
Insmed Signs Development Agreement With Phyton Biotech
Licensing Agreements
Insmed Enters Into Licensing Agreement With Tercica And Genentech
Insmed Enters Into Licensing Agreement With Tercica And Genentech
Insmed Enters Into Licensing Agreement With Napo Pharmaceuticals
Insmed Enters Into Licensing Agreement With Avecia
Insmed Enters Into Licensing Agreement With Tzamal
Insmed Enters Into A Licensing Agreement With Fujisawa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Insmed Incorporated – Pipeline by Therapy Area and Indication, 2010
Insmed Incorporated – Pipeline by Stage of Development, 2010
Insmed Incorporated – Monotherapy Products in Pipeline, 2010
Insmed Incorporated - Phase II, 2010
Insmed Incorporated - Phase I, 2010
Insmed Incorporated - Pipeline By Therapeutic Class, 2010
Insmed Incorporated - Pipeline By Target, 2010
Insmed Incorporated – Pipeline By Route of Administration, 2010
Insmed Incorporated – Pipeline By Molecule Type, 2010
Insmed Incorporated - Dormant Developmental Projects, 2010
Insmed Incorporated - Discontinued Pipeline Products, 2010
Insmed Incorporated, Subsidiaries
Insmed Incorporated, Deals Summary, 2004 to YTD 2010
Insmed Incorporated, Deals Summary by Region, 2004 to YTD 2010
Insmed Incorporated, Deals Summary, 2004 to YTD 2010 37
LIST OF FIGURES
Insmed Incorporated – Pipeline by Therapy Area and Indication, 2010
Insmed Incorporated – Pipeline by Stage of Development, 2010
Insmed Incorporated – Monotherapy Products in Pipeline, 2010
Insmed Incorporated – Pipeline By Therapeutic Class, 2010
Insmed Incorporated - Pipeline By Target, 2010
Insmed Incorporated – Pipeline By Route of Administration, 2010
Insmed Incorporated – Pipeline By Molecule Type, 2010 22